Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Therapeutic vaccine improves response rate and extends progression-free survival in patients with metastatic melanoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.07.09
Views: 14215

Dr Patrick Hwu - M.D. Anderson Cancer Center, US

Patrick Hwu, MD, Chair of the Department of Melanoma Medical Oncology M. D. Anderson Cancer Center: Therapeutic Vaccine Improves Response Rate and Extends Progression-Free Survival in Patients with Metastatic Melanoma: Preliminary findings from a phase III, multicenter trial show that adding a novel cancer vaccine – called gp100:209-217(210M) peptide – to standard therapy doubles response rates and extends progression-free survival in patients with metastatic melanoma, without causing significant side effects.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation